ENTPD1 and myeloid sarcoma: A longitudinal study on a cohort of relapsing RR-MS patients, both treated and untreated, found that CD39 activity was increased after four days of corticoid treatment19; however, comparison was between before and after corticoid treatment, but not with healthy subjects.